Key result
Pharmacological approaches for treating radiation injuries are in development, but practical and legal barriers, along with a lack of biodosimetry capabilities, currently prevent their clinical use.
Despite laboratory advances in pharmacological treatments for radiation injuries, significant practical, legal, and infrastructural barriers hinder their clinical application in emergency scenarios.
Answers are grounded in this paper and cite their sources.
Barriers block clinical use of radiation injury pharmacotherapies; leaves open the need for biodosimetry and regulatory advances.
PURPOSE: Events of the recent past have focused attention on the possibility of radiological (nuclear) terrorism and on the implications of such terrorist threats for radiation accident preparedness. This review discusses recent advances in the knowledge about how radiation injuries from such events might be treated pharmacologically, and the practical barriers to clinical utilization of these approaches. CONCLUSIONS: A wide range of pharmacological approaches are being developed in the laboratory that could greatly expand the ability to treat acute and chronic radiation injuries. However, there are currently a variety of practical and legal barriers that would prevent the actual clinical use of most of the approaches. There are also the potential weaknesses in most of the current programmes for dealing with the consequences of radiation accidents or nuclear terrorism, including the absence of widespread radiation biodosimetry capabilities and the resulting inability to triage. If a major radiation accident or terrorist event occurs, the lack of biodosimetry and treatment capabilities will be compounded by widespread public fear of 'radiation'.
No takes yet. Share an insight, caveat, or question.
J. E. Moulder (2004) conducted a review in Radiation injuries. Pharmacological approaches was evaluated. Pharmacological approaches for treating radiation injuries are in development, but practical and legal barriers, along with a lack of biodosimetry capabilities, currently prevent their clinical use.
Synapse has enriched 10 related papers. Consider them for comparative context: